| Priyanka Bikkina, | |
|
7901 S 12th St Ste 200, Portage, MI 49024-3831 | |
| (269) 341-8585 | |
| Not Available |
| Full Name | Priyanka Bikkina |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 10 Years |
| Location | 7901 S 12th St Ste 200, Portage, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023437043 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bronson Methodist Hospital | Kalamazoo, MI | Hospital |
| Bronson Lakeview Hospital | Paw paw, MI | Hospital |
| Bronson South Haven Hospital | South haven, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bronson Methodist Hospital | 0244148633 | 598 |
News Archive
Biosimilars are not generics and the Biologics Prescribers Collaborative (BPC) applauds the U.S. Food and Drug Administration (FDA) for recognizing that each biosimilar needs a distinguishable name in its draft guidance issued today. The FDA's draft guidance on nonproprietary naming of biological products proposes distinguishable names, calling for biological products to bear a nonproprietary name that includes an FDA-designated suffix.
Family Research Council condemned today's decision by the Obama administration to eliminate key provisions of a Bush administration regulation that enforced laws protecting the conscience rights of medical professionals who oppose abortion.
When a close friend shares bad news, our instinct is to help. But putting ourselves in a friend's shoes, imagining how we would feel if we were the one suffering, may have detrimental effects on our own health, according to a new study led by the University of Pennsylvania's Anneke E. K. Buffone.
Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.
› Verified 8 days ago
| Entity Name | Bronson Methodist Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417961137 PECOS PAC ID: 0244148633 Enrollment ID: O20031208000832 |
News Archive
Biosimilars are not generics and the Biologics Prescribers Collaborative (BPC) applauds the U.S. Food and Drug Administration (FDA) for recognizing that each biosimilar needs a distinguishable name in its draft guidance issued today. The FDA's draft guidance on nonproprietary naming of biological products proposes distinguishable names, calling for biological products to bear a nonproprietary name that includes an FDA-designated suffix.
Family Research Council condemned today's decision by the Obama administration to eliminate key provisions of a Bush administration regulation that enforced laws protecting the conscience rights of medical professionals who oppose abortion.
When a close friend shares bad news, our instinct is to help. But putting ourselves in a friend's shoes, imagining how we would feel if we were the one suffering, may have detrimental effects on our own health, according to a new study led by the University of Pennsylvania's Anneke E. K. Buffone.
Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.
› Verified 8 days ago
| Entity Name | Bronson Battle Creek Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093119638 PECOS PAC ID: 0547173478 Enrollment ID: O20041103000774 |
News Archive
Biosimilars are not generics and the Biologics Prescribers Collaborative (BPC) applauds the U.S. Food and Drug Administration (FDA) for recognizing that each biosimilar needs a distinguishable name in its draft guidance issued today. The FDA's draft guidance on nonproprietary naming of biological products proposes distinguishable names, calling for biological products to bear a nonproprietary name that includes an FDA-designated suffix.
Family Research Council condemned today's decision by the Obama administration to eliminate key provisions of a Bush administration regulation that enforced laws protecting the conscience rights of medical professionals who oppose abortion.
When a close friend shares bad news, our instinct is to help. But putting ourselves in a friend's shoes, imagining how we would feel if we were the one suffering, may have detrimental effects on our own health, according to a new study led by the University of Pennsylvania's Anneke E. K. Buffone.
Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Priyanka Bikkina, 601 John Street, Box 39, Kalamazoo, MI 49007 Ph: () - | Priyanka Bikkina, 7901 S 12th St Ste 200, Portage, MI 49024-3831 Ph: (269) 341-8585 |
News Archive
Biosimilars are not generics and the Biologics Prescribers Collaborative (BPC) applauds the U.S. Food and Drug Administration (FDA) for recognizing that each biosimilar needs a distinguishable name in its draft guidance issued today. The FDA's draft guidance on nonproprietary naming of biological products proposes distinguishable names, calling for biological products to bear a nonproprietary name that includes an FDA-designated suffix.
Family Research Council condemned today's decision by the Obama administration to eliminate key provisions of a Bush administration regulation that enforced laws protecting the conscience rights of medical professionals who oppose abortion.
When a close friend shares bad news, our instinct is to help. But putting ourselves in a friend's shoes, imagining how we would feel if we were the one suffering, may have detrimental effects on our own health, according to a new study led by the University of Pennsylvania's Anneke E. K. Buffone.
Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.
› Verified 8 days ago
William Francis Hanavan, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 3304 Cooley Ct, Portage, MI 49024 Phone: 269-349-2266 Fax: 269-349-0792 | |
Dr. Sarah Anne Wasserman, D.O. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3304 Cooley Ct, Portage, MI 49024 Phone: 269-349-2266 Fax: 269-349-0792 | |
Jeffrey M Coppinger, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2600 W Centre Ave, Portage, MI 49024 Phone: 269-324-4141 Fax: 269-324-2020 | |
Jaroslaw P Siwik, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2600 W Centre Ave, Bronson Internal Medicine Associates, Portage, MI 49024 Phone: 269-324-4141 Fax: 269-324-2020 | |
Dr. Deborah Esteves, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 7895 Currier Dr, Portage, MI 49002 Phone: 269-324-8670 Fax: 269-321-7154 | |
Todd J White, DO Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2600 W Centre Ave, Bronson Internal Medicine Associates, Portage, MI 49024 Phone: 269-324-4141 Fax: 269-324-2020 |